The study team described a clinicopathologic syndrome of enterocolitis occurring after treatment with cilta-cel, a BCMA-directed CAR T cell product used for relapsed and refractory multiple myeloma. Patients presented with severe diarrheal illness. Tissue analysis showed infiltration of clonal CAR+ T cells into the gastrointestinal mucosa, with a predilection for the duodenum. The authors framed this syndrome as a lymphoproliferative process rather than a simple inflammatory diarrhea.
Investigators reported nine cases of immune effector cell–associated enterocolitis (IEC-EC) among 158 patients treated with cilta-cel at MD Anderson Cancer Center, yielding an incidence of 5.1% at a 6-month landmark in that cohort. The authors also noted a global incidence figure of 5.7% reported across other datasets. Prior case reports and series are cited by the study team; regulatory action has followed, including an FDA labeling change that added a boxed warning for IEC-EC after cilta-cel.
The cohort showed monoclonal or oligoclonal CAR+ T cell populations in all cases, as measured by vector integration analysis, flow cytometry and T cell receptor sequencing. Vector integration analysis localized clonal insertions to introns of highly expressed genes. The authors explicitly reported no evidence that vector-mediated mutagenesis accounted for the proliferative phenotype. Driver mutations were described as sparse and heterogeneous across cases, distinguishing this entity from classical peripheral T cell lymphoma observed after some CAR therapies.
Patients who developed IEC-EC had markedly higher persistence of CAR+ T cells in peripheral blood compared with patients who did not develop enterocolitis. The authors reported roughly a 100-fold increase in circulating CAR T cell levels in affected patients. The study team therefore linked peripheral persistence quantitatively to tissue infiltration, suggesting an association between systemic CAR T cell burden and risk of mucosal clonal expansion.
RNA sequencing performed on mucosal infiltrates revealed upregulation of cytotoxic and inflammatory gene programs within the CAR+ compartment relative to control tissue. Data indicated active cytotoxicity and inflammatory signaling as cardinal features of the infiltrating clones. The authors interpreted these transcriptional signatures as consistent with a cytotoxic T cell–driven mucosal injury process rather than a purely regulatory or exhausted phenotype.
Clonal vector integrations were found in intronic regions of genes with high expression in the infiltrating cells. The study team did not find demonstrable evidence that these integrations caused insertional mutagenesis driving transformation. Instead, the pattern of integration and the scarcity and heterogeneity of candidate driver mutations led the investigators to conclude that IEC-EC is molecularly distinct from overt post-CAR T cell malignancies that have been linked to specific oncogenic integrations.
Authors contrasted IEC-EC with previously reported post-CAR peripheral T cell lymphomas. In this series, clonal architecture, integration-site distribution and mutation patterns diverged from the profiles described in bona fide T cell lymphomas after CAR therapy. The cohort’s molecular features—sparse, non-recurrent candidate driver mutations and intronic integrations in expressed genes—supported a model of clonal lymphoproliferation with cytotoxic activity rather than classical malignant transformation driven by a single recurrent oncogenic event.
The report places its findings alongside earlier case reports and regulatory updates: the FDA has updated cilta-cel labeling to include a boxed warning for IEC-EC. The authors documented a duodenum-predominant, clonal CAR+ cytotoxic T cell infiltration as the primary mechanism of IEC-EC in their series. Limitations were described in molecular resolution: driver mutations were few and heterogeneous, and the authors did not demonstrate vector-mediated oncogenesis. The source did not report detailed intervention protocols or standardized management algorithms for IEC-EC in this series. Open questions remain about the triggers for clonal expansion, the determinants of tissue tropism to the duodenum, and whether specific integration-site patterns confer functional advantages that promote mucosal homing or survival. These represent concrete knowledge gaps and next steps for investigators and regulators tracking post–CAR T cell toxicities.